502 related articles for article (PubMed ID: 28987804)
21. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
Fogarty C; Hattersley H; Di Scala L; Drollmann A
Respir Med; 2011 Mar; 105(3):337-42. PubMed ID: 21144724
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.
Leaker BR; Barnes PJ; Jones CR; Tutuncu A; Singh D
Br J Clin Pharmacol; 2015 Mar; 79(3):492-500. PubMed ID: 25243340
[TBL] [Abstract][Full Text] [Related]
23. Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.
Fukushima Y; Nakatani Y; Ide Y; Sekino H; St Rose E; Siddiqui S; Maes A; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1187-1194. PubMed ID: 29695902
[TBL] [Abstract][Full Text] [Related]
24. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
[TBL] [Abstract][Full Text] [Related]
26. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
Hvisdas C
Am J Health Syst Pharm; 2021 Jun; 78(13):1184-1194. PubMed ID: 33821890
[TBL] [Abstract][Full Text] [Related]
27. Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis.
Liu B; Zan S; Luo W
Heart Lung; 2022; 52():52-60. PubMed ID: 34875569
[TBL] [Abstract][Full Text] [Related]
28. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
[TBL] [Abstract][Full Text] [Related]
29. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.
Singh D; Pujol H; Ribera A; Seoane B; Massana E; Astbury C; Ruiz S; de Miquel G
BMC Pulm Med; 2014 Nov; 14():176. PubMed ID: 25398689
[TBL] [Abstract][Full Text] [Related]
30. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
Vogelmeier C; Verkindre C; Cheung D; Galdiz JB; Güçlü SZ; Spangenthal S; Overend T; Henley M; Mizutani G; Zeldin RK
Pulm Pharmacol Ther; 2010 Oct; 23(5):438-44. PubMed ID: 20416390
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
Beier J; van Noord J; Deans A; Brooks J; Maden C; Baggen S; Mehta R; Cahn A
Int J Chron Obstruct Pulmon Dis; 2012; 7():153-64. PubMed ID: 22419863
[TBL] [Abstract][Full Text] [Related]
32. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
van Geffen WH; Carpaij OA; Westbroek LF; Seigers D; Niemeijer A; Vonk JM; Kerstjens HAM
Respir Med; 2020 Sep; 171():106064. PubMed ID: 32917359
[TBL] [Abstract][Full Text] [Related]
33. Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.
Ferguson GT; Feldman G; Pudi KK; Barnes CN; Moran EJ; Haumann B; Pendyala S; Crater G
Chronic Obstr Pulm Dis; 2019 Apr; 6(2):154-165. PubMed ID: 30974049
[TBL] [Abstract][Full Text] [Related]
34. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
36. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
Joos GF; Aumann JL; Coeck C; Korducki L; Hamilton AL; Kunz C; Aalbers R
Respir Med; 2015 May; 109(5):606-15. PubMed ID: 25776199
[TBL] [Abstract][Full Text] [Related]
37. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
[TBL] [Abstract][Full Text] [Related]
38. Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).
Beeh KM; Emirova A; Prunier H; Santoro D; Nandeuil MA
Int J Chron Obstruct Pulmon Dis; 2018; 13():1701-1711. PubMed ID: 29872288
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD.
Bateman ED; Kornmann O; Ambery C; Norris V
Pulm Pharmacol Ther; 2013 Oct; 26(5):581-7. PubMed ID: 23538170
[TBL] [Abstract][Full Text] [Related]
40. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.
Rennard S; Fogarty C; Reisner C; Fernandez C; Fischer T; Golden M; Rose ES; Darken P; Tardie G; Orevillo C
BMC Pulm Med; 2014 Jul; 14():118. PubMed ID: 25027304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]